目的 探讨纳入国家医保谈判（以下简称“国谈”）药品目录的新型抗肿瘤药物在山西省的可获得性及使用情况，为后续省级政策优化提供数据支撑。方法 收集2022—2024年山西省“国谈”新型抗肿瘤药物使用数据，运用描述性统计分析方法，对356家公立二、三级医院“国谈”新型抗肿瘤药物的可获得率、用药金额、用药频度（DDDs）、日均费用（DDC）及排序比（B/A）指标进行分析。结果 “国谈”新型抗肿瘤药物整体可获得率逐年上升，三级医院的获得率明显高于二级医院，但可获得率中位数评价均为“非常低”。与2022年相比，2023年“国谈”新型抗肿瘤药物的药物利用指标DDDs和用药金额分别增长32.39%和31.68%，2024年DDDs和用药金额分别增长40.54%和24.65%，DDC整体呈现不同程度的下降趋势，3种国产新药替雷利珠单抗、信迪利单抗、卡瑞利珠单抗其销售金额和DDDs值均位于排名前5内，且B/A＞1。结论 “国谈”新型抗肿瘤药物在山西省的可获得率不高，利用情况2年来呈合理上升趋势，省级卫生主管部门应优化“国谈”药品政策的落地实施，提高可获得率，同时加强临床合理用药监管。

Objective To investigate the availability and utilization of new anticancer drugs included in the national medical insurance negotiation drug list in Shanxi province, and to provide data support for subsequent provincial policy optimization.Merhods The data of the use of new anticancer drugs drugs in the province from 2022 to 2024 were collected. Descriptive statistical analysis was used to analyze the indicators such as availability rate, expense, DDDs, DDC, and B/A of new anticancer drugs in 356 secondary and tertiary public general hospitals in Shanxi province.Results The overall availability rate of national negotiation new anticancer drugs were increased. Availability rate of tertiary general hospitals was significantly higher than that of secondary general hospitals, but the median evaluation of the availability rate was “very low”. Compared with 2022, the drug utilization index DDDs and drug expenditure of national negotiation new anticancer drugs in 2023 were increased by 32.39% and 31.68%, increased by 40.54% and 24.65% in 2024, and DDC showed a downward trend to varying degrees. The expense and DDDs of three domestic new drugs for tirellizumab, sintilizumab, and camrelizumab were all in the top five, and B/A > 1.Conclusion The availability rate of new national negotiation anticancer drugs is not high in Shanxi province, and consumption shows a reasonable upward trend in the past two years. The provincial health authorities should optimize the implementation of the drug policy, improve the availability, and strengthen the supervision of rational clinical drug use.

R979.1

山西省大健康产业高质量发展科研专项课题（DJKZXKT2023264）；国家卫生健康委医院管理研究所医院药学高质量发展研究项目（NIHAYS2428）